CARLSBAD, Calif.--(BUSINESS WIRE)--Life Technologies Corporation (NASDAQ: LIFE) today announced that its Applied Biosystems™ 3500 Dx Series Genetic Analyzers, the first CE IVD-marked capillary electrophoresis system for nucleic acid analysis, are now available for sale in Australia, India, New Zealand, Singapore, and Taiwan.

The 3500 Dx Series Genetic Analyzers are intended for use in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility. The 3500 Series enables researchers to run up to 1,100 sequencing or 1,200 genotyping samples per day. It features a novel consumables design that incorporates the ability to track key information with radio frequency identification (RFID) tags, new optical and thermal sub-systems, and redesigned data collection and analysis software, creating a more cost-effective method for high-quality data analyses.

“We are very excited to see the 3500 Dx Genetic Analyzer be accepted and approved for sale across the Asia Pacific Region,” said Mark Smedley, head of the Asia Pacific region for Life Technologies. “Life Technologies is proud to be working with these nations, providing them with enabling genetic sequencing systems and is committed to advancing human health and combating critical human diseases like cancer.”

The 3500 Dx Series Genetic Analyzers are part of a broader portfolio of advanced genomic technologies that are built upon Applied Biosystems' legacy of providing platforms that are recognized for proven technology, reliability and performance. They provide an integrated solution that combines the instrument with Applied Biosystems reagents, consumables, software, and world class service and support.

The 3500 Dx platform is also available in the following European countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Luxembourg, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland, and the United Kingdom.

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.